We do not publish a verdict for Medline Inc (MDLN) and Resmed Inc (RMD) is slightly undervalued.
We publish an intrinsic value for RMD but not for MDLN, so the two cannot be ranked on price.
Values as of the 22 Sept 2026 close.
We do not publish a value for this company: it has no growth history of its own to project.
Leak Score 29/100 on 5 of 12 signals
Discounting its cash flows at 9.0% (average of 3 methods) values the shares at $239.56; the price of $221.97 is 7% below that value, and 76% of that value comes from beyond year five.
Leak Score 75/100 on 10 of 12 signals
| Metric | MDLN | RMD |
|---|---|---|
| Verdict | Not valued | Slightly undervalued |
| Price | $34.43 | $221.97 |
| Intrinsic value | — | $239.56 |
| Margin of safety | — | +7% |
| Leak Score | 29/100 (5/12) | 75/100 (10/12) |
| Market cap | $45.3B | $32.0B |
| Revenue growth, 5 years | — | 12.1% |
| Operating margin | 6.5% | 34.0% |
| Net margin | 2.3% | 26.9% |
| Return on equity | 4.9% | 24.3% |
| Debt to equity | 1.09 | 0.13 |
| P/E | 40.4x | 21.3x |
| Forward P/E | 21.8x | 16.7x |
| P/B | 2.6x | 4.9x |
| Dividend yield | 0.1% | 1.2% |